MRD at Intercell Outdoor: Hadone Invites 2022

(1:51:58)

MRD at Intercell x Partiboi69 pres. Area 69 | ADE 2023

(1:52:30)

The real world utilization of MRD in myeloma across Europe

(1:27)

MRD in Acute Lymphoblastic Leukemia: Where do we Stand

(49:11)

Workshops on CLL and MRD at ERIC 2020

(1:54)

The role of MRD in ALL: what defines a complete response?

(3:35)

Decrease Patient Stress: Keep MRD in the Academic Setting

(59)

The value of MRD in transplant-ineligible patients with multiple myeloma

(1:4)

The future of myeloma: the potential role of MRD-driven therapy de-escalation strategies

(57)

Dr. Stone Discusses Monitoring MRD in AML

(1:34)

Dr. Radich on Impact of MRD in Acute Vs Chronic Leukemias

(1:5)

Implementing MRD in clinical practice for patients with intermediate-risk AML

(1:42)

Dr. Brammer on the Importance of MRD in Relapsed/Refractory ALL

(1:15)

The use of clonoSEQ to monitor MRD in patients with LBCL treated with axi-cel in ZUMA-7

(1:25)

Approaches to and the use of MRD in ALL

(5:17)

MRD in myeloma: the FDA perspective

(1:26)

The importance of MRD in multiple myeloma in guiding treatment decisions \u0026 access to therapies

(3:10)

Determining the optimal threshold to test MRD in multiple myeloma

(2:31)

Haploidentical transplantation for AML with MRD at transplantation

(2:)

The evolving role of MRD in DLBCL

(2:30)